Hangzhou Tigermed Consulting Co., Ltd
Shenzhen Stock ExchangeTotal Valuation
Hangzhou Tigermed Consulting Co., Ltd carries a market capitalization of 36.08B, placing it among publicly traded companies globally. Its enterprise value stands at 50.65B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 36.08B |
| Enterprise Value | 50.65B |
Share Statistics
Hangzhou Tigermed Consulting Co., Ltd currently has 861.03M shares outstanding.
| Shares Outstanding | 861.03M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Hangzhou Tigermed Consulting Co., Ltd trades at a trailing price-to-earnings ratio of 157.07. The price-to-sales ratio is 7.15, and the price-to-book ratio stands at 4.80.
| PE Ratio | 157.07 |
| PS Ratio | 7.15 |
| PB Ratio | 4.80 |
| P/TBV Ratio | 2.28 |
| P/FCF Ratio | 182.01 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Hangzhou Tigermed Consulting Co., Ltd trades at an EV/EBITDA multiple of 69.61 and an EV/FCF ratio of 198.53. The EV/Sales ratio of 7.80 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 69.61 provides insight into valuation relative to core operating earnings.
| EV / Sales | 7.80 |
| EV / EBITDA | 69.61 |
| EV / EBIT | 69.61 |
| EV / FCF | 198.53 |
Financial Position
Hangzhou Tigermed Consulting Co., Ltd maintains a current ratio of 1.83, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.83 |
| Quick Ratio | 0.54 |
| Debt / Equity | 10.82 |
| Debt / EBITDA | 3.56 |
| Interest Coverage | N/A |
Financial Efficiency
Hangzhou Tigermed Consulting Co., Ltd posts a return on equity of 3.06 and a return on invested capital of 1.61.
| Return on Equity (ROE) | 3.06 |
| Return on Assets (ROA) | 1.00 |
| Return on Invested Capital (ROIC) | 1.61 |
| Return on Capital Employed (ROCE) | 2.06 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 140.13 |
Taxes
Over the trailing twelve months, Hangzhou Tigermed Consulting Co., Ltd has paid 163.98M in income taxes, reflecting an effective tax rate of 39.32.
| Income Tax | 163.98M |
| Effective Tax Rate | 39.32 |
Stock Price Statistics
Hangzhou Tigermed Consulting Co., Ltd's stock has declined approximately -7.71844% over the past 52 weeks. The 50-day moving average sits at 45.58, while the 200-day moving average is 53.76.
| Beta (5Y) | N/A |
| 52-Week Price Change | -7.71844% |
| 50-Day Moving Average | 45.58 |
| 200-Day Moving Average | 53.76 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Hangzhou Tigermed Consulting Co., Ltd generated 6.50B in revenue and converted that into 295.63M in net income, yielding earnings per share of 0.29. EBITDA reached 727.64M, while operating income came in at 727.64M.
| Revenue | 6.50B |
| Gross Profit | 1.89B |
| Operating Income | 727.64M |
| Pretax Income | 417.06M |
| Net Income | 295.63M |
| EBITDA | 727.64M |
| EBIT | 727.64M |
| Earnings Per Share (EPS) | 0.29 |
Balance Sheet
Hangzhou Tigermed Consulting Co., Ltd holds 1.82B in cash and equivalents against 2.59B in total debt, resulting in a net debt position of 263.30M. Total book value stands at 9.68B, with working capital of 2.81B providing operational flexibility.
| Cash & Cash Equivalents | 1.82B |
| Total Debt | 2.59B |
| Net Debt | 263.30M |
| Equity (Book Value) | 9.68B |
| Book Value Per Share | 11.11 |
| Working Capital | 2.81B |
Cash Flow
After subtracting -255.12M in capital expenditures, free cash flow totaled -255.12M - equivalent to -0.29 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -255.12M |
| Free Cash Flow | -255.12M |
| FCF Per Share | -0.29 |
Margins
Hangzhou Tigermed Consulting Co., Ltd operates with a gross margin of 29.05, reflecting its pricing power and cost economics. The operating margin of 11.20 and net profit margin of 4.55 provide insight into operational efficiency.
| Gross Margin | 29.05 |
| Operating Margin | 11.20 |
| Pretax Margin | 6.42 |
| Profit Margin | 4.55 |
| EBITDA Margin | 11.20 |
Dividends & Yields
The company's payout ratio of 403.51 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.98 |
| Dividend Yield | N/A |
| Payout Ratio | 403.51 |
| Shareholder Yield | 5.89 |
| FCF Yield | 0.55 |
Stock Splits
Hangzhou Tigermed Consulting Co., Ltd's most recent stock split took place on July 1, 2019 with a 2:3 split ratio.
| Last Split Date | 7/1/2019 |
| Split Ratio | 2:3 |
Scores
Hangzhou Tigermed Consulting Co., Ltd posts an Altman Z-Score of 7.12, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.12 |